Sugi Predict

Sugi Predict / Compounds / SCHEMBL21800531

SCHEMBL21800531

SCHEMBL21800531

COC(=O)C(C)C1CCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 8/20 0.49
▸ EPHX1 P07099 1/20 0.48
▸ ALDH1A1 P00352 3/20 0.44
▸ MAPT P10636 2/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ EED O75530 1/20 0.44
▸ RBBP4 Q09028 1/20 0.44
▸ SUZ12 Q15022 1/20 0.44
▸ EZH2 Q15910 1/20 0.44
▸ AEBP2 Q6ZN18 1/20 0.44
▸ HPGD P15428 1/20 0.43
▸ RECQL P46063 1/20 0.42
▸ USP30 Q70CQ3 1/20 0.41
▸ PTPN2 P17706 1/20 0.41
▸ PTPN1 P18031 1/20 0.41
▸ PTPN6 P29350 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30835882 1.00 GPR119 (0.49) GPR119EPHX1ALDH1A1MAPTNPC1
SCHEMBL11931409 0.92 EPHX1 (0.49) GPR119EPHX1ALDH1A1MAPTNPC1
SCHEMBL3821259 0.91 EPHX1 (0.54) GPR119EPHX1ALDH1A1MAPTNPC1
SCHEMBL19074507 0.87 GPR119 (0.48) GPR119EPHX1ALDH1A1MAPTNPC1
SCHEMBL22655482 0.87 GPR119 (0.48) GPR119EPHX1ALDH1A1MAPTNPC1
SCHEMBL2612117 0.87 GPR119 (0.46) GPR119EPHX1ALDH1A1MAPTNPC1
SCHEMBL30543771 0.86 EPHX1 (0.45) GPR119EPHX1ALDH1A1MAPTNPC1
SCHEMBL13300114 0.85 GPR119 (0.48) GPR119EPHX1ALDH1A1MAPTNPC1
SCHEMBL27157592 0.85 GPR119 (0.48) GPR119EPHX1ALDH1A1MAPTNPC1
SCHEMBL27204263 0.85 GPR119 (0.48) GPR119EPHX1ALDH1A1MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025059577-A1 SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS ATAVISTIK BIO, INC. (US) 2025-03-20 — — WO disclosed
CN-119285572-A Kinase inhibitors and uses thereof 戴纳立制药公司 2025-01-10 — — CN disclosed
US-20250011338-A1 Kinase Inhibitors and Uses Thereof DENALI THERAPEUTICS INC. (US) 2025-01-09 — — US disclosed
CN-119264073-A Kinase inhibitors and uses thereof 戴纳立制药公司 2025-01-07 — — CN disclosed
EP-4472968-A1 INHIBITORS OF RAF KINASES PIERRE FABRE MEDICAMENT (FR) 2024-12-11 — — EP disclosed
US-12129263-B2 Kinase inhibitors and uses thereof DENALI THERAPEUTICS INC. (US) 2024-10-29 — — US disclosed
CN-110913858-B Kinase inhibitors and uses thereof 戴纳立制药公司 2024-09-24 — — CN disclosed
US-20240182467-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2024-06-06 — — US disclosed
CN-117980293-A Hydroxamic acid compound with ENPP1 inhibitory activity and application thereof 上海海和药物研究开发股份有限公司 2024-05-03 — — CN disclosed
US-11814384-B2 Inhibtors of Raf kinases KINNATE BIOPHARMA INC. (US) 2023-11-14 — — US disclosed
US-20230303566-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2023-09-28 — — US disclosed
WO-2023150681-A1 INHIBITORS OF RAF KINASES KINNATE BIOPHARMA INC. (US) 2023-08-10 — — WO disclosed
WO-2023036289-A1 HYDROXAMIC ACID COMPOUND HAVING ENPP1 INHIBITORY ACTIVITY AND USE THEREOF 上海海和药物研究开发股份有限公司 2023-03-16 — — WO disclosed
US-20220041620-A1 Kinase Inhibitors and Uses Thereof DENALI THERAPEUTICS INC. (US) 2022-02-10 — — US disclosed
US-11203600-B2 Kinase inhibitors and uses thereof DENALI THERAPEUTICS INC. (US) 2021-12-21 — — US disclosed
US-11203600-B2 Kinase inhibitors and uses thereof DENALI THERAPEUTICS INC. (US) 2021-12-21 — — US disclosed
CN-110913858-A Kinase inhibitors and uses thereof 戴纳立制药公司 2020-03-24 — — CN disclosed
US-20200087319-A1 Kinase Inhibitors and Uses Thereof DENALI THERAPEUTICS INC. (US) 2020-03-19 — — US disclosed
US-20200087319-A1 Kinase Inhibitors and Uses Thereof DENALI THERAPEUTICS INC. (US) 2020-03-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011338-A1 Kinase Inhibitors and Uses Thereof MAP3K20, MAP3K6, MAP3K19 GPR119 2770/4885EPHX1 2814/4885ALDH1A1 4295/4885
US-20240182467-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF GPR119 1300/4885EPHX1 1517/4885ALDH1A1 2750/4885
US-20230303566-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF GPR119 1300/4885EPHX1 1517/4885ALDH1A1 2750/4885
US-20200087319-A1 Kinase Inhibitors and Uses Thereof MAP3K20, MAP3K6, MAP3K19 GPR119 2770/4885EPHX1 2814/4885ALDH1A1 4295/4885
US-11203600-B2 Kinase inhibitors and uses thereof MAP3K20, MAP3K6, MAP3K19 GPR119 2770/4885EPHX1 2814/4885ALDH1A1 4295/4885
US-20220041620-A1 Kinase Inhibitors and Uses Thereof MAP3K20, MAP3K6, MAP3K19 GPR119 2770/4885EPHX1 2814/4885ALDH1A1 4295/4885
US-11814384-B2 Inhibtors of Raf kinases RAF1, BRAF, ARAF GPR119 789/4885EPHX1 2594/4885ALDH1A1 2477/4885
US-12129263-B2 Kinase inhibitors and uses thereof MAP3K20, MAP3K6, MAP3K19 GPR119 2770/4885EPHX1 2814/4885ALDH1A1 4295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.